



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

1. Name of Inspector from whom received : Mr. R. Vanlalruata, Assistant Director (F and D)
OFFICE OF CHIEF MEDICAL OFFICER,,
AIZAWL, MIZORAM, PIN:-796017.
2. Serial No. and date of Inspector's memorandum : 126/IPA-AZL E/III-2025 , 22-SEP-2025
3. Number of Sample : NIL
4. Date of receipt : 08-OCT-2025
5. Names of drugs purporting to be contained in the sample : Nitrofurantoin Sustained Release Tablets 100 mg
(Nitrofurantoin-100)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2025-26/1300	GUW/LS/2025-26/1254	LGP03/183/12	Mar-2025 Feb-2027	NA	Logos Pharma, Village Maissa Tibba, Tehsil Nalagarh, District Solan (H.P.) -174101

6. Condition of seals on : Seals were intact & identical to the
[the packet or on portion of sample or container] specimen impression of the seal received
from Drugs Inspector

7. Result of test or analysis with protocols or test or analysis applied : Please see below

Date of Testing : From 20-Feb-2026 To 23-Feb-2026

COMPOSITION : Each film coated sustained release tablet contains:
Nitrofurantoin IP 100 mg

Protocol Applied : I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	Yellow colored, round, bi-convex, film coated tablets, in blister pack.	NA
2	Identification	Gives positive test for Nitrofurantoin.	NA
3	Average weight	0.17956 g	NA
4	Uniformity of weight	Complies.	+7.5 % of Average weight

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
-------	-----------------	-------	-------	------------	--------	--------------------

1	Nitrofurantoin	99.73 mg/Tablet	100 mg/Tablet	99.73	90 % to 110 %	I.P. 2022
---	----------------	-----------------	------------------	-------	---------------	-----------

In the opinion of the undersigned the sample referred to above **is of standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per I.P. 2022 in respect of test performed.

Date: 02-MAR-2026


GOVERNMENT ANALYST
Rinku Kalita
Medical Device Testing Officer
R.D.T.L., Guwahati-22

-----END OF REPORT-----

